Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan

Chen‐Hua Liu(National Taiwan University Hospital), Jia‐Horng Kao(National Taiwan University Hospital), Chun‐Chao Chang(Taipei Medical University Hospital), Tsai‐Yuan Hsieh(Tri-Service General Hospital), Wei‐Yu Kao(Taipei Medical University Hospital), Chung‐Hsin Chang(Fu Jen Catholic University), Chi-Wei Tseng(Tzu Chi University), Pei‐Lun Lee(Jacobi Medical Center), Po‐Yueh Chen(Chia-Yi Christian Hospital), Jow-Jyh Hwang(St. Martin de Porres Hospital), Jo‐Hsuan Wu(University of California San Diego), Kuo‐Chih Tseng(Buddhist Tzu Chi General Hospital), Chi‐Yang Chang(E-Da Hospital), Chi-Yi Chen(Chia-Yi Christian Hospital), Sheng‐Shun Yang(Taichung Veterans General Hospital), Hao‐Tsai Cheng(Chang Gung University), Cheng‐Yuan Peng(China Medical University), Wei‐Wen Su(Taichung Veterans General Hospital), Chun‐Jen Liu(National Taiwan University), Jyh-Jou Chen(Chi Mei Medical Center), Pei–Yuan Su(Changhua Christian Hospital), Ke-Jhang Huang(China Medical University), Ming‐Chang Tsai(Chung Shan Medical University Hospital), Gin‐Ho Lo(E-Da Hospital), Yi‐Jie Huang(Taichung Veterans General Hospital), Hsueh‐Chou Lai(China Medical University), Chia‐Sheng Huang(Kaohsiung Medical University), Yu‐Lueng Shih(Tri-Service General Hospital), Fu‐Jen Lee(Fu Jen Catholic University), Yu‐Jen Fang(National Taiwan University), Hung‐Da Tung(Center for HIV and Hepatogastroenterology)
Hepatology International
January 26, 2023
Cited by 21


Related Papers